Half-off sale at Eli Lilly as drug rebating climbs to 51% by Eric Sagonowsky Friday, March 30, 2018 Jockeying for market share, Eli Lilly offered more than half off its U.S. list prices in the form of rebates and discounts last year.
With jump to CVS, ex-Lilly exec Rice joins Witty in payer industry by Eric Sagonowsky Wednesday, March 21, 2018 Former Eli Lilly CFO Derica Rice becomes the second top Big Pharma ex to take the reins at a major pharmacy benefit manager.
Allergan CEO nabs $32.8M despite tribal licensing debacle by Eric Sagonowsky Wednesday, March 14, 2018 Despite sliding share prices and an ill-fated tribal licensing deal, CEO Brent Saunders nabbed compensation eight times higher than his 2016 pay.
UnitedHealthcare to let consumers share in drug rebates by Eric Sagonowsky Tuesday, March 6, 2018 UnitedHealthcare is planning to offer rebates directly back to millions of patients—a move that addresses a top criticism from the drug industry.
Lilly CEO amassed $15.8M in pay as sales grew and payroll shrank by Tracy Staton Friday, March 2, 2018 After Lilly CEO David Ricks took over in 2016, he revamped management while cutting costs and jobs—and earned nearly $16 million in pay for his efforts.
Trump pledges new HHS chief will push drug prices 'way down' by Eric Sagonowsky Tuesday, January 30, 2018 Does industry still fear the threat of pricing reform from the Trump Administration?
PhRMA boosts lobbying spend by 30% in 2017 by Eric Sagonowsky Wednesday, January 24, 2018 As the drug industry took heat in 2017 for "getting away with murder," among other criticisms, its lobbyists were busy behind the scenes.
Drug discounting soars from 28% to 41% in 5 years: report by Arlene Weintraub Tuesday, January 23, 2018 Payer discounts are likely to grow even if midterm elections revive attacks on the industry—and investors should be worried about that, analysts say.
Lilly CEO to pharma: Stop talking and get going on pricing by Eric Sagonowsky Wednesday, January 10, 2018 Merck & Co.'s top executive said Monday that pricing pressure isn't likely to get worse. But Eli Lilly CEO David Ricks begs to differ.
JPM need-to-know: Lilly, Novartis, Dynavax, Aimmune and more by Tracy Staton Monday, January 8, 2018 The 2018 J.P. Morgan Healthcare Conference is receding in biopharma's rearview mirror, but industry watchers have only begun digesting the commentary.